SK Bioscience Co Ltd - Asset Resilience Ratio
SK Bioscience Co Ltd (302440) has an Asset Resilience Ratio of 28.99% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how SK Bioscience Co Ltd's Asset Resilience Ratio has changed over time. Check how strategically is SK Bioscience Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down SK Bioscience Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 302440 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩847.30 Billion | 28.99% |
| Total Liquid Assets | ₩847.30 Billion | 28.99% |
Asset Resilience Insights
- Very High Liquidity: SK Bioscience Co Ltd maintains exceptional liquid asset reserves at 28.99% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
SK Bioscience Co Ltd Industry Peers by Asset Resilience Ratio
Compare SK Bioscience Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for SK Bioscience Co Ltd (2018–2024)
The table below shows the annual Asset Resilience Ratio data for SK Bioscience Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 29.73% | ₩845.41 Billion ≈ $572.92 Million |
₩2.84 Trillion ≈ $1.93 Billion |
-32.19pp |
| 2023-12-31 | 61.92% | ₩1.15 Trillion ≈ $777.38 Million |
₩1.85 Trillion ≈ $1.26 Billion |
+3.31pp |
| 2022-12-31 | 58.62% | ₩1.26 Trillion ≈ $850.85 Million |
₩2.14 Trillion ≈ $1.45 Billion |
-14.73pp |
| 2021-12-31 | 73.34% | ₩1.55 Trillion ≈ $1.05 Billion |
₩2.11 Trillion ≈ $1.43 Billion |
+40.66pp |
| 2020-12-31 | 32.68% | ₩183.74 Billion ≈ $124.52 Million |
₩562.23 Billion ≈ $381.02 Million |
+12.85pp |
| 2019-12-31 | 19.82% | ₩80.09 Billion ≈ $54.27 Million |
₩403.98 Billion ≈ $273.77 Million |
-4.81pp |
| 2018-12-31 | 24.63% | ₩99.19 Billion ≈ $67.22 Million |
₩402.71 Billion ≈ $272.91 Million |
-- |
About SK Bioscience Co Ltd
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the preve… Read more